Improved clinical control of a challenging case of Behçet's disease with rituximab therapy

Clinical Rheumatology

Volumn 33, Issue 1, 2014, Pages 149-150

  Zhao, Barbara Hong ^a   Oswald, Anna Elfiky ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Beh et's disease; Biologics; Rituximab

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB;

ADD ON THERAPY; ADULT; ARTHRITIS; BEHCET DISEASE; BONE MARROW BIOPSY; CASE REPORT; DISEASE ACTIVITY; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ERYTHEMA NODOSUM; FEMALE; FEVER; HUMAN; MONONEUROPATHY MULTIPLEX; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SKIN BIOPSY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINALYSIS; YOUNG ADULT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS; BEHCET SYNDROME; BIOLOGICAL PRODUCTS; COLCHICINE; CYCLOPHOSPHAMIDE; ERYTHEMA NODOSUM; FEMALE; HUMANS; PREDNISONE; STEROIDS; TREATMENT OUTCOME; ULCER;

EID: 84897668484     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2433-x     Document Type: Review

References (15)

1. Ohno S et al (2004) Behçet's disease with refractory uveoretinitis. J Rheumatol 31(7):1362-1368
2. Arida A et al (2011) Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61-7
3. Benitah NR, Sobrin L, Papaliodis GN (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol 26(4-5):295-303
4. Marsh EA, Davies LM, Llewelyn JG (2012) How to recognise and treat peripheral nervous system vasculitis. Pract Neurol. doi:10.1136/ practneurol-2012-000464
5. Takeuchi A, Kodama M, Takatsu M, Hashimoto T, Miyashita H (1989) Mononeuritis multiplex in incomplete Behçet's disease a case report and the review of the literature. Clin Rheumatol 8:375-380
6. Sadreddini S (2008) Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 18:306-308
7. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246-52
8. Yazici Y, Yazici H (2010) Behcet's syndrome. Springer, London
9. Demirkesen C, TüzünerN,Mat C, Senocak M, Büyü kbabaniN, Tüzün Y, Yazici H (2001) Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol 116(3):341-6
10. Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 272(1-2):99-105
11. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y (2010) Efficacy of combination therapy of anti-TNF-a antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21(2):184-91
12. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32(1):98-105
13. Miserocchi E, Pontikaki M, Modorati M, Gattinara M, Meroni PL, Gerloni V (2011) Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11:35-39
14. Saadouna D, Bodaghib B, Bienvenuc B, Wechslera B, Sened D, Trade S, Abadf S, Cacouba P, Kodjikiang L, Sève P (2013) Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. 12(7):774-783
15. Kose O (2012) Development of immunopathogenesis strategies to treat Behçet's disease. Pathol Res Int 2012, 261989. doi:10.1155/ 2012/261989, 7 pages